Top

Published in:

01-04-2015 | Research Article

Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer

Authors: Xiaobin Gu, Tian Tian, Bo Zhang, Yang Liu, Chao Yuan, Lijuan Shao, Yajun Guo, Kexing Fan

Published in: Tumor Biology | Issue 4/2015

Abstract

Interleukin-35 (IL-35) has recently been implicated in tumor immunity. The aim of this study was to explore the clinical role of plasma IL-35 in patients with non-small cell lung cancer (NSCLC). Plasma collected from 106 patients with NSCLC cases and 78 healthy controls (HC) were subjected to IL-35 enzyme-linked immunosorbent assay (ELISA) and relationships between plasma IL-35 levels and clinical characteristics were evaluated. The correlation of IL-35 and overall survival was analyzed using Kaplan–Meier method. The prognostic value of IL-35 was tested using univariate and multivariate analysis. Circulating IL-35 levels were significantly higher in the NSCLC group in comparison with the HC group (21.37 ± 11.55 pg/ml vs. 10.09 ± 5.32 pg/ml, p < 0.001). Correlation analysis by subgroup indicated that plasma IL-35 correlated positively with tumor TNM stage (p < 0.001) and lymph node metastases (p < 0.0001). Using a cutoff level of 20.26 pg/ml (median value), IL-35 showed an inverse correlation with overall survival. Univariate and multivariate analysis indicated that plasma IL-35 was an independent prognostic factor for NSCLC patients. Circulating IL-35 in NSCLC patients significantly increased. IL-35 is a promising potential biomarker in prognostication of clinical outcome of NSCLC patients and the regulation of IL-35 expression may provide a new target for the treatment of NSCLC patients.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Canc J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRef

Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V. Non small cell lung cancer (NSCLC): current status and future prospects. Indian J Chest Dis Allied Sci. 2004;46(3):191–203.PubMed

Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Canc Cell. 2012;21(3):448.e2. doi:10.1016/j.ccr.2012.03.007.

Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol Offic J Am Soc Clin Oncol. 1995;13(5):1221–30.CrossRef

Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566–U19. doi:10.1038/nature06306.CrossRefPubMed

Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA. 1997;94(22):12041–6. doi:10.1073/pnas.94.22.12041.CrossRefPubMedPubMedCentral

Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021–9. doi:10.1002/eji.2007378101.CrossRefPubMed

Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11(12):1093–U97. doi:10.1038/ni.1952.CrossRefPubMedPubMedCentral

Wang ZH, Liu JQ, Liu ZZ, Shen RL, Zhang GQ, Xu JP, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013;190(5):2415–23. doi:10.4049/jimmunol.1202535.CrossRefPubMedPubMedCentral

10.

Shen P, Roch T, Lampropoulou V, O’Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366–70. doi:10.1038/nature12979.CrossRefPubMedPubMedCentral

11.

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48. doi:10.1016/j.immuni.2004.07.017.CrossRefPubMed

12.

Devergne O, Coulomb-L’Hermine A, Capel F, Moussa M, Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol. 2001;159(5):1763–76. doi:10.1016/s0002-9440(10)63023-4.CrossRefPubMedPubMedCentral

13.

Poleganov MA, Bachmann M, Pfeilschifter J, Muhl H. Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor. Mol Immunol. 2008;45(10):2869–80. doi:10.1016/j.molimm.2008.01.021.CrossRefPubMed

14.

Niedobitek G, Pazolt D, Teichmann M, Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol. 2002;198(3):310–6. doi:10.1002/path.1217.CrossRefPubMed

15.

Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, et al. Identification of Epstein-Barr virus-induced gene 3 as a novel plasma and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011;17(19):6272–86. doi:10.1158/1078-0432.ccr-11-0060.CrossRefPubMed

16.

Jin P, Ren H, Sun W, Xin W, Zhang H, Hao JH. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol. 2014;75(1):29–33. doi:10.1016/j.humimm.2013.09.018.CrossRefPubMed

17.

Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013;6(9):1806–16.PubMedPubMedCentral

18.

Wu H, Li P, Shao N, Ma J, Ji M, Sun X, et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-beta in acute myeloid leukemia. Oncol Lett. 2012;3(5):1119–23. doi:10.3892/ol.2012.614.PubMedPubMedCentral

19.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(6):645–53. quiz 53.PubMed

20.

Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184(12):7144–53. doi:10.4049/jimmunol.0902739.CrossRefPubMedPubMedCentral

21.

Long J, Zhang XL, Wen MJ, Kong QL, Lv Z, An YQ, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun. 2013;430(1):364–9. doi:10.1016/j.bbrc.2012.11.004.CrossRefPubMed

Title: Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer
Authors: Xiaobin Gu
Tian Tian
Bo Zhang
Yang Liu
Chao Yuan
Lijuan Shao
Yajun Guo
Kexing Fan
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2887-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma

High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma

Genome-wide haplotype association study identifies BLM as a risk gene for prostate cancer in Chinese population

TFF3 and HER2 expression and their correlation with survival in gastric cancer

Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes

Correlation between squamous cell carcinoma of the lung and human papillomavirus infection and the relationship to expression of p53 and p16

Keynote webinar | Spotlight on antibody–drug conjugates in cancer